Magazine Article | April 1, 2022

Drug Product CDMO Selection Metrics Point Toward Pandemic-Induced Concern

Source: Life Science Leader

By Industry Standard Research

ISR’s annual CDMO Benchmarking research asks participants to identify the CDMO attributes that factor into their service-provider selection decisions. This year’s data point toward concerns about assurance of supply when it comes to sterile injectables among both small molecule and biologic drug product outsourcers. Having capacity to meet sponsors’ demands and reliable, on-time delivery occupy the top of the lists. This is not surprising, given the increase in demand for vaccine production brought about by the COVID-19 pandemic.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: